Goldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $240
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has maintained a Neutral rating on United Therapeutics (NASDAQ:UTHR) and raised the price target from $218 to $240.

May 03, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on United Therapeutics but increases the price target from $218 to $240.
The increase in price target by Goldman Sachs suggests a positive outlook on the stock's future performance, potentially leading to increased investor interest and a short-term positive impact on the stock price. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, balancing the potential for significant short-term price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100